PulseAugur
EN
LIVE 10:27:32

New Bayesian detector finds cancer resistance in ctDNA below detection limits

By PulseAugur Editorial · [2 sources] ·

Researchers have developed a new Bayesian change-point detector called Span, designed to analyze serial circulating-tumour DNA (ctDNA) data. This method treats non-detects as left-censored observations, enabling the detection of drug resistance earlier than traditional methods. In simulations for metastatic breast cancer, Span approximately doubled the detection rate of impending progressions three months in advance compared to snapshot analyses. AI

IMPACT This new statistical method could improve early detection of drug resistance in cancer patients by leveraging intermittent ctDNA signals.

RANK_REASON The cluster contains a research paper detailing a new statistical method.

Read on arXiv cs.LG →

AI-generated summary · Google Gemini · from 2 sources. How we write summaries →

New Bayesian detector finds cancer resistance in ctDNA below detection limits

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Research
The cluster contains a research paper detailing a new statistical method.
Source corroboration
2 independent sources
Multiple independent publishers reporting the same story raises confidence that it's real and newsworthy.
Topics
paper, safety
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
High
Clearly on-topic for AI-industry coverage.
Story freshness
82 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [2]

  1. arXiv cs.LG TIER_1 English(EN) · Aarchi Singh Thakur, Abhijoy Sarkar ·

    Seeing Below the Limit of Detection: A Censored-Poisson Bayesian Latent-Growth Change-Point Detector (the Span Detector) for Serial ctDNA in HR+/HER2- Metastatic Breast Cancer

    arXiv:2606.11876v1 Announce Type: cross Abstract: Circulating-tumour DNA (ctDNA) carries evidence of drug resistance months before imaging shows it, but the earliest evidence lives below the assay's limit of detection (LoD): a nascent subclone is detected only intermittently, pro…

  2. arXiv cs.LG TIER_1 English(EN) · Abhijoy Sarkar ·

    Seeing Below the Limit of Detection: A Censored-Poisson Bayesian Latent-Growth Change-Point Detector (the Span Detector) for Serial ctDNA in HR+/HER2- Metastatic Breast Cancer

    Circulating-tumour DNA (ctDNA) carries evidence of drug resistance months before imaging shows it, but the earliest evidence lives below the assay's limit of detection (LoD): a nascent subclone is detected only intermittently, producing a flickering sequence of faint detects and …

RELATED ENTITIES

RELATED TOPICS